Download PDF
Thromb Haemost 1974; 32(02/03): 306-324
DOI: 10.1055/s-0038-1647701
Original Article
Schattauer GmbH

Substrate Composition and the Effect of ε-Aminocaproic Acid on Tissue Plasminogen Activator and Urokinase-induced Fibrinolysis

Sixtus Thorsen   *
1   James F. Mitchell Foundation, Institute for Medical Research, Washington, D. C. 20015
,
Tage Astrup
1   James F. Mitchell Foundation, Institute for Medical Research, Washington, D. C. 20015
› Author Affiliations
Further Information

Publication History

Received 18 February 1974

Accepted after resubmission 06 June 1974

Publication Date:
30 June 2018 (online)

    Permissions and Reprints

Summary

The influence of variations in substrate composition on the biphasic pattern of inhibition by e-aminocaproic acid (EACA) of urokinase-induced fibrinolysis, first observed on bovine plasminogen-rich fibrin, was studied using a fibrin clot lysis time assay. Different species of fibrinogen and plasminogen or plasmin were used. Preparations of different degrees of purification were compared at varying concentrations. The behavior of urokinase was compared with that of a porcine tissue plasminogen activator. Variations in the conditions of the assay greatly influenced the results. The concentration of fibrinogen had a particularly marked influence. At increased fibrinogen concentrations the biphasic response of urokinase was enhanced and a weak biphasic effect was also produced by the tissue activator which usually yields a uniformly increasing inhibition curve. The phase of fibrinolysis enhancement produced by urokinase with genuine plasminogen substrates occurs at substrate concentrations and EACA levels present in patients treated with EACA. The observed variations may explain discordant findings reported by various investigators.

* Current address: Department of Clinical Chemistry, Blegdamshospitalet, Copenhagen, Denmark


 

  • References

  • 1 Abiko Y, Iwamoto M. 1970; Plasminogen-plasmin system VII. Potentiation of anti fibrinolytic action of a synthetic inhibitor, tranexainic acid, by a2-macroglobulin antiplasmin. Biochimica et Biophysica Acta 214: 411.
    CrossrefPubMedGoogle Scholar
  • 2 Abiko Y, Iwamoto M, Shimizu M. 1968; Plasminogen-plasmin system I. Purification and properties of human plasminogen. Journal of Biochemistry (Tokyo) 64: 743.
    PubMedGoogle Scholar
  • 3 Abiko Y, Iwamoto M, Tomikawa M. 1969; Plasminogen-plasmin system V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. Biochimica et Biophysica Acta 185: 424.
    CrossrefPubMedGoogle Scholar
  • 4 Ablondi F. B, Hagan J. J, Philips M, De Renzo E. C. 1959; Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by s-aminocaproic acid. Archives of Biochemistry and Biophysics 82: 153.
    CrossrefPubMedGoogle Scholar
  • 5 Alkjaersig N, Fletcher A. P, Sherry S. 1959; e-aminocaproic acid: an inhibitor of plasminogen activation. Journal of Biological Chemistry 234: 832.
    PubMedGoogle Scholar
  • 6 Ambrus C. M, Ambrtts J. L, Lassman H. B, Mink I. B. 1970; On the heterogeneity of activity of various types of plasmins and the spectra of inhibition of some plasmin inhibitors. Research Communications in Chemical Pathology and Pharmacology 01: 67.
    PubMedGoogle Scholar
  • 7 Andersson L, Nilsson I. M, Colleen S, Granstrand B, Melander B. 1968; Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCHA. Annals of the New York Academy of Sciences 146: 642.
    CrossrefPubMedGoogle Scholar
  • 8 Bennett N. B. 1967; A method for the quantitative assay of inhibitor of plasminogen activation in human serum. Thrombosis et Diathesis Haemorrhagica 17: 12.
    PubMedGoogle Scholar
  • 9 Blix S. 1962; The effectiveness of activators in clot lysis, with special reference to fibrinolytic therapy. Acta Medica Scandinavica 172 suppl. 386.
    PubMedGoogle Scholar
  • 10 Blombäck B, Blombäck M. 1956; Purifications of human and bovine fibrinogen. Arkiv for Kemi 10: 415.
    PubMedGoogle Scholar
  • 11 Brakman P. 1965; Bovine fibrinogen without detectable plasminogen. Analytical Biochemistry 11: 149.
    CrossrefPubMedGoogle Scholar
  • 12 Brakman P. 1967 Fibrinolysis. A Standardized Fibrin Plate Method and a Fibrinolytic Assay of Plasminogen. Scheltema and Holkema N. V., Amsterdam..
    PubMedGoogle Scholar
  • 13 Brakman P, Astrup T. 1971. The fibrin plate method for assay of fibrinolytic agents. In: Bang N. U, Beller F. K, Deutsch E, Mammen E. F. (eds.) Thrombosis and Bleeding Disorders. Academic Press; New York: 332.
    Google Scholar
  • 14 Brockway W. J, Castellino F. J. 1971; The mechanism of the inhibition of plasmin activity by e-aminocaproic acid. Journal of Biological Chemistry 246: 4641.
    PubMedGoogle Scholar
  • 15 Camiolo S. M. 1971 A Comparative Study of Fibrinogenolysis and Fibrinolysis and the Influence of Inhibitors. University Microfilms Ltd. Ann Arbor, Michigan..
    PubMedGoogle Scholar
  • 16 Celander D. R, Naschke M. D, Guest M. M. 1961; The effect of s-aminocaproic acid on fibrinolysin and on activators of profibrinolysin. Texas Reports on Biology and Medicine 19: 50.
    PubMedGoogle Scholar
  • 17 Claeys H, Molla A, Verstraete M. 1973 Digestion of human plasminogen by human plasmin. IVth International Congress on Thrombosis and Haemostasis. June 19-22nd, Vienna, Austria, Abstract #153..
    PubMedGoogle Scholar
  • 18 Collen D, Tytgat G, Claeys H, Yerstraete M, Wallen P. 1972; Metabolism of plasminogen in healthy subjects: Effect of tranexamic acid. The Journal of Clinical Investigation 51: 1310.
    CrossrefPubMedGoogle Scholar
  • 19 Doleschel W, Auerswald W, von Lützow A. 1962; On the inhibiting effect of e-aminocaproic acid upon the fibrinolytic system during ’spontaneous activation. Thrombosis et Diathesis Haemorrhagica 08: 101.
    PubMedGoogle Scholar
  • 20 Dubber A. H.C, McNicol G. P, Douglas A. S. 1965; Amino methyl cyclohexane carboxylic acid (AMCHA). A new synthetic fibrinolytic inhibitor. British Journal of Haematology 11: 237.
    PubMedGoogle Scholar
  • 21 Egeblad K. 1966; Effects of epsilon-aminocaproic acid on fibrin clot lysis. Thrombosis et Diathesis Haemorrhagica 15: 173.
    PubMedGoogle Scholar
  • 22 Ende N, Auditore J. V. 1963; Circulating fibrinolytic activator and hemorrhagic diathesis. Annals of Surgery 158: 117.
    CrossrefPubMedGoogle Scholar
  • 23 Geratz J. D. 1973; Structure-activity relationships for the inhibition of plasmin and plasminogen activation by aromatic diamidines and a study of the effect of plasma proteins on the inhibition process. Thrombosis et Diathesis Haemorrhagica 29: 154.
    PubMedGoogle Scholar
  • 24 Kok P, Astrup T. 1969; Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Biochemistry 08: 79.
    CrossrefPubMedGoogle Scholar
  • 25 Kok P, Astrup T. 1972; Differentiation between plasminogen activators by means of epsilon-aminocaproic acid. Thrombosis et Diathesis Haemorrhagica 27: 77.
    PubMedGoogle Scholar
  • 26 Lukasiewicz H, Niewiarowski S, Worowski K, Lipinski B. 1968; The plasmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate. Biochimica et Biophysica Acta 159: 503.
    CrossrefPubMedGoogle Scholar
  • 27 McNicol G. P, Fletcher A. P, Alkjaersig N, Sherry S. 1962; The absorption, distribution, and excretion of e-aminocaproic acid following oral or intravenous administration to man. Journal of Laboratory and Clinical Medicine 59: 15.
    PubMedGoogle Scholar
  • 28 Maki M, Beller F. K. 1966; Comparative studies of fibrinolytic inhibitors in vitro. Thrombosis et Diathesis Haemorrhagica 16: 668.
    PubMedGoogle Scholar
  • 29 Maxwell R. E, Lewandowski Y, Nickel V. S. 1965; Enhancement of fibrinolysis and antagonism of antiplasmin by reversible plasmin inhibitors. Life Sciences 04: 45.
    CrossrefPubMedGoogle Scholar
  • 30 Maxwell R. E, Nawrocki J. W, Nickel V. S. 1968; Some complexities of multiple inhibitor interactions in fibrinolytic systems. Thrombosis et Diathesis Haemorrhagica 19: 117.
    PubMedGoogle Scholar
  • 31 Mosesson M. W, Finlayson J. S. 1963; Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. Journal of Clinical Investigation 42: 747.
    CrossrefPubMedGoogle Scholar
  • 32 Oshiba S, Okamoto S. 1962; Influence of AMCHA on the activity of fibrinolysin (plasmin). Keio Journal of Medicine 11: 117.
    CrossrefPubMedGoogle Scholar
  • 33 Rabiner S. F, Goldfine I. D, Hart A, Summaria L, Robbins K. C. 1969; Radioimmunoassay of human plasminogen and plasmin. The Journal of Laboratory and Clinical Medicine 74: 265.
    PubMedGoogle Scholar
  • 34 Sjoerpsma A, Nilsson I. M. 1958; Aliphatic amino compounds as inhibitors of plasminogen activation. Proceedings of the Society for Experimental Biology and Medicine 103: 533.
    PubMedGoogle Scholar
  • 35 Skoza L, Tse A. O, Semar M, Johnson A. J. 1968; Comparative activities of amino acid and polypeptide inhibitors on natural and synthetic substrates. Annals of the New York Academy of Sciences 146: 659.
    CrossrefPubMedGoogle Scholar
  • 36 Thorsen S. 1973; The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects. The Scandinavian Journal of Clinical and Laboratory Investigation 31: 51.
    PubMedGoogle Scholar
  • 37 Thorsen S, Astrup T. 1969; Biphasic inhibition of urokinase-induced fibrinolysis by e-aminocaproic acid; distinction from tissue plasminogen activator. Proceedings of the Society for Experimental Biology and Medicine 130: 811.
    PubMedGoogle Scholar
  • 38 Thorsen S, Kok P, Astrup T. 1972 Molecular alterations of plasminogen disclosed by the effects of e-aminocaproic acid (EACA) on fibrinolysis and caseinolysis induced by urokinase (UK). Federation Proceedings. 31. 229 (Abstract no. 106)
    PubMedGoogle Scholar
  • 39 Thorsen S, Kok P, Astrup T. 1974 Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to s-aminocaproic acid. Thrombosis et Diathesis Haemorrhagica. 32..
    PubMedGoogle Scholar
  • 40 Wallen P, Wiman B. 1972; Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochimica et Biophysica Acta 257: 122.
    PubMedGoogle Scholar
  • 41 Wallen P, Wiman B. 1973. On the formation and properties of an intermediate form of human plasminogen generated during activation with urokinase. IVth International Congress on Thrombosis and Haemostasis. June 19-22nd, Vienna, Austria: Abstract no. 150..
    Google Scholar